NewsBenzinga에보뮤네, 유럽피부과학회 및 성병학회 학술대회에서 중등도~중증 아토피 피부염 환자를 대상으로 한 EVO301 2a상 연구 결과 발표 예정 에보뮤네, 유럽피부과학회 및 성병학회 학술대회에서 중등도~중증 아토피 피부염 환자를 대상으로 한 EVO301 2a상 연구 결과 발표 예정 Benzinga 2026.09.23 20:06 (GMT+0) Open on Benzinga Other news AEON Biopharma Q3 EPS $0.01 Beats $(0.08) Estimate STOP-HS1 And STOP-HS2 Trials Evaluating Safety And Efficacy Of Povofortay In Patients With Moderate To Severe HS Met The Primary Endpoint Cable One Receives Non-Compliance Notice From NYSE Cadiz Q3 EPS $(0.18) Misses $(0.14) Estimate, Sales $1.572M Miss $2.710M Estimate MDU Resources Anticipates Issuing Equity Of ~$70M In 2027 And $100M In 2028 To Support Near-Term Capital Expenditures PagSeguro Digital Q3 Adj. EPS $0.43 Beats $0.41 Estimate, Sales $989.696M Miss $996.200M Estimate
STOP-HS1 And STOP-HS2 Trials Evaluating Safety And Efficacy Of Povofortay In Patients With Moderate To Severe HS Met The Primary Endpoint
MDU Resources Anticipates Issuing Equity Of ~$70M In 2027 And $100M In 2028 To Support Near-Term Capital Expenditures